Acrivon Therapeutics, Inc. Common Stock (ACRV) Earnings Analysis

Acrivon Therapeutics, Inc. Common Stock (ACRV) next reports earnings on 2026-08-12, consensus EPS -0.49 USD. Last quarter (2026-03-19) it beat with EPS -0.49 USD vs -0.49 USD est (0%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -0.84.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ACRV next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.49 USD
Revenue estimate0.00B

ACRV earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-19-0.49 USD-0.49 USD0%Beat
2025-11-13-0.47 USD-0.57 USD+17.5%Beat
2025-08-13-0.55 USD-0.57 USD+3.5%Beat
2025-05-14-0.51 USD-0.57 USD+10.5%Beat
2024-11-13-0.59 USD-0.56 USD-5.4%Miss

Beat rate: 4/5 (80%) over reported quarters with consensus data.

ACRV valuation and analyst view

Trailing P/E-0.84
Trailing EPS-1.99528 USD
Price / book0.68
Dividend yield0.00%
Market cap0.05B
Analyst consensusBuy (9 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is Acrivon Therapeutics, Inc. Common Stock (ACRV)'s next earnings date?

Acrivon Therapeutics, Inc. Common Stock is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.49 USD and revenue estimate of 0.00B.

Did ACRV beat earnings last quarter?

In its 2026-03-19 report, ACRV posted EPS of -0.49 USD versus a -0.49 USD estimate — a beat of 0%.

What is ACRV's earnings track record?

Over the last 5 reported quarters with consensus data, ACRV beat estimates 4 times (80%).

What is ACRV's current P/E ratio and EPS?

ACRV trades at a trailing P/E of -0.84 on trailing EPS of -1.9952845208792929 USD.

What do analysts rate ACRV?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell).